Merit Medical Systems (NASDAQ:MMSI) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Merit Medical Systems (NASDAQ:MMSI) had its price target raised by equities researchers at JPMorgan Chase & Co. from $95.00 to $110.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 27.55% from the company’s previous close.

Several other research firms have also recently issued reports on MMSI. Weiss Ratings upgraded shares of Merit Medical Systems from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, October 12th. Bank of America raised their price objective on shares of Merit Medical Systems from $92.00 to $97.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Freedom Capital initiated coverage on Merit Medical Systems in a report on Tuesday. They set a “hold” rating for the company. Zacks Research lowered shares of Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a report on Monday, October 19th. Finally, Piper Sandler upped their price target on shares of Merit Medical Systems from $96.00 to $106.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $105.55.

Merit Medical Systems Stock Performance

MMSI stock traded down $7.15 during mid-day trading on Friday, hitting $86.24. 1,804,091 shares of the company were exchanged, compared to its average volume of 793,302. Merit Medical Systems has a 1-year low of $59.74 and a 1-year high of $94.85. The business has a 50 day simple moving average of $88.68 and a 200-day simple moving average of $77.12. The stock has a market capitalization of $5.15 billion, a PE ratio of 35.64, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.04 by $0.08. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The firm had revenue of $416.24 million for the quarter, compared to analyst estimates of $410.56 million. During the same quarter in the prior year, the firm earned $0.92 EPS. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. On average, equities analysts forecast that Merit Medical Systems will post 3.84 earnings per share for the current year.

Hedge Funds Weigh In On Merit Medical Systems

Several hedge funds and other institutional investors have recently made changes to their positions in MMSI. Kilter Group LLC acquired a new stake in Merit Medical Systems during the second quarter worth approximately $25,000. Salomon & Ludwin LLC grew its stake in Merit Medical Systems by 140.8% during the 3rd quarter. Salomon & Ludwin LLC now owns 537 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 314 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Merit Medical Systems by 88.6% during the 3rd quarter. IFP Advisors Inc now owns 694 shares of the medical instruments supplier’s stock worth $60,000 after purchasing an additional 326 shares during the last quarter. Harbor Investment Advisory LLC bought a new stake in shares of Merit Medical Systems in the 2nd quarter worth approximately $50,000. Finally, Pinnacle Wealth Planning Services Inc. lifted its position in shares of Merit Medical Systems by 84.0% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 784 shares of the medical instruments supplier’s stock worth $68,000 after buying an additional 358 shares during the period. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems News Summary

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Strong Q3 earnings beat expectations. Merit reported third-quarter revenue of $416.2 million, up 8.4% year over year and ahead of the $410.6 million consensus estimate. Non-GAAP EPS was $1.12 versus expectations of $1.04, while GAAP EPS rose 51% to $0.70. Merit Medical Q3 2026 results
• Positive Sentiment: Profitability and cash generation improved. Organic constant-currency revenue increased 9%, GAAP operating margin expanded to 14.1% from 11.1%, and year-to-date operating cash flow reached $175.2 million, with $129.5 million in free cash flow.
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 earnings outlook following the strong quarter, supporting expectations for continued growth. Merit Medical raises 2026 guidance
• Positive Sentiment: Analysts raised targets. BTIG Research lifted its target from $105 to $110 and maintained a buy rating. Wells Fargo raised its target from $83 to $92, although it retained an equal-weight rating. Analysts raise Merit Medical price targets
• Positive Sentiment: Cardiac-therapy capabilities expanded. Merit acquired Solo Pace, adding temporary pacing technology designed for patients with aortic stenosis and strengthening its TAVR-related product portfolio. Merit Medical acquires Solo Pace
• Neutral Sentiment: Valuation remains a consideration. With the stock trading at roughly 36 times earnings and near its 52-week high, investors may be demanding continued execution, leaving limited room for disappointment.
• Negative Sentiment: Some caution remains among analysts. Wells Fargo’s equal-weight rating and the company’s narrowed sales outlook temper the bullish impact of the earnings beat and guidance increase.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a medical device company that develops, manufactures and distributes disposable products used in interventional, diagnostic and therapeutic procedures. Its devices are designed for use by healthcare professionals in hospitals, outpatient facilities and other clinical settings.

The company’s product portfolio includes devices for vascular access, angiography, intervention, drainage, embolization, oncology and cardiac procedures. Merit also offers products used in peripheral intervention, spine procedures and other specialized areas of minimally invasive medicine, including kits, accessories and related procedural equipment.

Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical serves healthcare providers through a global commercial and manufacturing network.